Neoplasms, Germ Cell and Embryonal clinical trials

The registry lists 166 studies for Neoplasms, Germ Cell and Embryonal across more than 10 countries. 48 are recruiting or about to start. 63 of them are mainly about Neoplasms, Germ Cell and Embryonal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 48 narrower conditions too, such as Melanoma: 9,194 studies, 1,950 open.

Get an email when these change. Save the Neoplasms, Germ Cell and Embryonal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 61
Recruiting: 40
Terminated: 18
Status unknown: 17
Active, not recruiting: 13
Not yet recruiting: 8

Phase

Phase 2: 73
Phase 1: 45
Phase 3: 9
Early Phase 1: 4
Phase 4: 1

Where

United States: 94
France: 20
United Kingdom: 15
Italy: 13
China: 12
Spain: 12

Who runs them

Seattle Children's Hospital (6) · National Cancer Institute (NCI) (6) · St. Jude Children's Research Hospital (5) · National Cancer Institute, Slovakia (5) · Memorial Sloan Kettering Cancer Center (5) · Children's Oncology Group (4) · Emory University (4) · Indiana University (4)

What is being tested here

Drugs under test in Neoplasms, Germ Cell and Embryonal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cisplatin	3	3	7
Etoposide	3	3	7
Bleomycin	2	2	2
Paclitaxel	1	0	7
Carboplatin	1	2	6
Cyclophosphamide	1	0	3
Olaparib	1	0	2
Filgrastim	1	1	2
G 207	1	0	2
Oncolytic HSV-1 G207	1	0	2

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Alkylating agents 1 open · Antimitotic agents 1 open · Antimetabolites 1 open · Immune checkpoint inhibitors 6

Coming up

5phase 3 studies under way

20studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jun 2027Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors · Phase 3 · Children's Oncology Group
Nov 2026Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors · Memorial Sloan Kettering Cancer Center
Dec 2026The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen · Wake Forest University Health Sciences
Dec 2026Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. · Chengcheng Guo
Dec 2026Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies · New York Medical College
Jan 2027A Study of miRNA 371 in Patients With Germ Cell Tumors · SWOG Cancer Research Network
Feb 2027C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) · Baylor College of Medicine
Mar 2027B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · St. Jude Children's Research Hospital
Apr 2027SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours · Imperial College London
May 2027Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors · Seattle Children's Hospital

Who these studies take

Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger. 22 (55%) take children under 18. 0 (0%) are for women only and 10 (25%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 40
Age	Women	Men
10	16 (40%)	17 (43%)
18	29 (73%)	39 (98%)
30	21 (53%)	30 (75%)
40	18 (45%)	27 (68%)
50	18 (45%)	27 (68%)
65	17 (43%)	25 (63%)
75	16 (40%)	24 (60%)
85	15 (38%)	23 (57%)

Across all 166 studies, recruiting or not: 43% stop at 75 or younger and 37% at 65; 52% take children; 2% are for women only and 22% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neoplasms, Germ Cell and Embryonal studies take

Of 25 phase 2 interventional studies under Neoplasms, Germ Cell and Embryonal, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	77 mo57–92 · 24 studies	—	—
Phase 2	51 mo35–83 · 25 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Stopped1

Multidisciplinary Approach to FatigueTerminatedOct 26, 2026NCT05502224

Newly registered1

A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNov 10, 2026NCT07928258

Studies

Recruiting first, then most recently updated. Showing 50 of 166. Browse all 166 → or search them.